Clinical Trials Browser

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT00330759 2022-11-07

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Phase 3 Completed

1,779 enrolled 14 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Spinal Cord Compression

NCT03408652 2021-10-22

MOSCAR

Phase 3 Terminated

1 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01077154 2021-09-28

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Phase 3 Terminated

4,509 enrolled 25 charts

Breast

Breast Neoplasms

NCT04859569 2021-06-07

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Phase 3 Unknown

850 enrolled

Other solid neoplasm

Bone Metastases From Solid Tumors

NCT03027557 2021-05-25

DENOCINA

Phase 3 Completed

46 enrolled 49 charts

Head & Neck

Parathyroid Neoplasms, Hyperparathyroidism, Primary

NCT04550949 2020-09-22

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Phase 3 Unknown

700 enrolled

Bone Metastases

NCT01419717 2019-09-24

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Phase 3 Completed

129 enrolled 10 charts

BreastGenitourinary

Breast Neoplasms, Neoplasms, Prostatic Neoplasms

NCT00838201 2018-10-18

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Phase 3 Completed

384 enrolled 8 charts

Genitourinary

Carcinoma, Neoplasms, Prostatic Neoplasms

NCT00089661 2018-10-17

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Phase 3 Completed

252 enrolled 13 charts

Breast

Bone Diseases, Metabolic, Breast Neoplasms

NCT00089674 2018-10-17

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Phase 3 Completed

1,468 enrolled 24 charts

Genitourinary

Prostatic Neoplasms

NCT00286091 2018-10-17

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Phase 3 Completed

1,435 enrolled 15 charts

Genitourinary

Hormone Refractory Prostate Cancer

NCT00980174 2018-10-17

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

Phase 3 Completed

242 enrolled 19 charts

Endocrine

Bone Diseases, Metabolic, Osteoporosis, Multiple Endocrine Neoplasia Type 1

NCT00321620 2018-08-29

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

Phase 3 Completed

1,904 enrolled 15 charts

Fractures, Bone

NCT03259152 2017-08-24

D-Gct

Phase 3 Unknown

30 enrolled

Giant Cell Tumor of Bone

NCT00925600 2017-05-30

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Phase 3 Completed

769 enrolled 21 charts

Genitourinary

Bone Diseases, Metabolic, Cataract, Neoplasms, Osteoporosis, Prostatic Neoplasms

NCT01920568 2017-01-16

A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors

Phase 3 Completed

487 enrolled 13 charts

Fractures, Bone

NCT01824342 2015-03-05

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Phase 3 Completed

18 enrolled 13 charts

Genitourinary

Castrate-resistant Prostate Cancer

NCT00950911 2014-02-11

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Phase 3 Completed

35 enrolled 8 charts

BreastGenitourinaryPlasma cell

Breast Neoplasms, Multiple Myeloma, Neoplasms, Prostatic Neoplasms

Clinical Trials

DenosuMast

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

BRCA-P

SPLENDOUR

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

MOSCAR

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

DENOCINA

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

D-Gct

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only